Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CanAg Antigen (Glycoform of MUC1) (None)
- Target
- None
- Molecular classification
- Glycoprotein, Tumor-associated antigen
01
Overview
CanAg is a tumor-associated antigen representing a specific cancer-associated glycoform of the MUC1 protein. This aberrant glycosylation pattern, distinct from normal MUC1, makes it a valuable target for cancer immunotherapy, particularly antibody-drug conjugates and CAR-T cell therapies. It's overexpressed in various solid tumors and contributes to oncogenic signaling and immune evasion.
- Other names
- Mucin 1 (MUC1)Polymorphic epithelial mucin (PEM)Epithelial membrane antigen (EMA)KL-6PUMPEMTMAM6
02
Mechanism of action
Antibody-drug conjugate targeting MUC1 glycoform, delivering cytotoxic payload.
03
Biological functions
Cell signalingImmune evasionProtection against pathogens (normal tissue)Oncogenic signaling (cancer)
04
Disease associations
Cancer (Colon, Breast, Ovarian, Lung, Pancreatic)
05
Safety considerations
Off-target toxicityImmunogenicityManageable toxicity profiles
06
Interacting drugs
Cantuzumab mertansine
07
Biomarkers
MUC1 overexpressionAberrant glycosylation (Tn-antigen, sialyl-Tn)
Beyond the preview
Go deeper on CanAg Antigen (Glycoform of MUC1) (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CanAg Antigen (Glycoform of MUC1) (None).